Strata Critical Medical, Inc.
- SRTA · Nasdaq
- Transportation Services
- New York, NY
- 601 employees
- CIK 0001779128
Updated from SEC filings through
Top things to know
Executives
- Will Heyburn Co-CEO and CFO 8-K, 2026-11-03
-
Melissa M. Tomkiel Co-CEO and General Counsel 4, 2026-09-25 -
William A. Heyburn Co-CEO and CFO 4, 2026-09-25 -
Louis R. Verdetto CEO, Clinical Services 4, 2026-09-10 -
Scott M. Wunsch CEO, Logistics 4, 2026-09-10 -
Amir Cohen Chief Accounting Officer 4, 2026-09-10
What leadership is saying
“Given Strata's improved cash generation coupled with the receipt of our first passenger sale earn-out, we are now in a position to both accelerate our target pace of acquisitions as well as opportunistically return cash to shareholders through our new buyback program”
Earnings press release (8-K Ex. 99.1), filed November 3, 2026
Strata Critical Medical, Inc. is a U.S. public company in transportation services (SIC 4700), headquartered in New York, NY. It trades as SRTA on Nasdaq. Revenue was $197M in the fiscal year ending December 31, 2025, +34.3% from the year before. It reported about 601 employees. Will Heyburn is Co-CEO and CFO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $197M 10-K, 2026-03-03 | $147M 10-K, 2026-03-03 | $225M 10-K, 2025-03-13 | $146M 10-K, 2024-03-12 | $50.5M 10-K, 2023-03-16 |
| Operating income | -$22.4M 10-K, 2026-03-03 | -$22.5M 10-K, 2026-03-03 | -$68.1M 10-K, 2025-03-13 | -$53.5M 10-K, 2024-03-12 | -$24.1M 10-K, 2023-03-16 |
| SG&A | $60.9M 10-K, 2026-03-03 | $50.9M 10-K, 2026-03-03 | $106M 10-K, 2025-03-13 | $70.3M 10-K, 2024-03-12 | $32.9M 10-K, 2023-03-16 |
| Net income | $41.3M 10-K, 2026-03-03 | -$27.3M 10-K, 2026-03-03 | -$56.1M 10-K, 2025-03-13 | -$27.3M 10-K, 2024-03-12 | -$40.1M 10-K, 2023-03-16 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Will Heyburn | Co-CEO and CFO | 8-K, 2026-11-03 |
| Melissa M. Tomkiel | Co-CEO and General Counsel | 4, 2026-09-25 |
| William A. Heyburn | Co-CEO and CFO | 4, 2026-09-25 |
| Louis R. Verdetto | CEO, Clinical Services | 4, 2026-09-10 |
| Scott M. Wunsch | CEO, Logistics | 4, 2026-09-10 |
| Robert S. Wiesenthal | Board member (per proxy) bio: Non-Executive Chairman of the Board of Directors and Former CEO | DEF 14A, 2026-04-14 |
| Amir Cohen | Chief Accounting Officer | 4, 2026-09-10 |
| Amir M. Cohen | Chief Accounting Officer | 10-K, 2026-03-03 |
| Andrew Lauck | Board member (per proxy) bio: Managing Partner and Co-Founder at Maple Park Capital Partners | DEF 14A, 2026-04-14 |
| Andrew C. Lauck | Board member (per proxy) bio: director | DEF 14A, 2026-04-14 |
What Strata Critical Medical, Inc. does
(f/k/a Blade Air Mobility, Inc.) (“Strata” or the “Company”) is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated “one call” solution for donor organ recovery.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 89.3 million (as of October 26, 2026) | 10-Q, November 3, 2026 |
|---|---|---|
| Public float | $264M (as of June 30, 2025) | 10-K, March 3, 2026 |
| Reportable segments | 2 (period ending September 30, 2026) | 10-Q, November 3, 2026 |
| Latest proxy statement | Meeting May 28, 2026 (filed April 14, 2026) | DEF 14A, April 14, 2026 |
| Auditor | Deloitte & Touche LLP (New York, New York) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 5, 2026 | Andrew Lauck Director | Buy | 2,000 | $10K | Form 4, November 9, 2026 |
| August 10, 2026 | Reginald Love Director | Sale | 5,091 | $29K | Form 4, August 13, 2026 |
| June 8, 2026 | William A. Heyburn Co-CEO and CFO | Sale | 31,671 | $186K | Form 4, June 10, 2026 |
| June 8, 2026 | Amir Cohen Chief Accounting Officer | Sale | 4,655 | $27K | Form 4, June 10, 2026 |
| June 8, 2026 | Melissa M. Tomkiel Co-CEO and General Counsel | Sale | 29,730 | $175K | Form 4, June 10, 2026 |
| June 8, 2026 | Scott M. Wunsch CEO, Logistics | Sale | 5,550 | $33K | Form 4, June 10, 2026 |
| May 22, 2026 | Amir Cohen Chief Accounting Officer | Sale | 50,875 | $299K | Form 4, May 26, 2026 |
| May 11, 2026 | Amir Cohen Chief Accounting Officer | Sale | 14,306 | $83K | Form 4, May 13, 2026 |
Recent 8-K events
- 8-K filed 2026-11-03
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-03
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-03
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-05
- Item 1.01 Entry into a material definitive agreement
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-12-03
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-11-10
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-09-16
- Item 1.01 Entry into a material definitive agreement
- Item 2.01 Completion of acquisition or disposition of assets
- Item 3.02 Unregistered sales of equity securities
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-08-29
- Item 1.01 Entry into a material definitive agreement
- Item 2.01 Completion of acquisition or disposition of assets
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
Frequently asked questions about Strata Critical Medical, Inc.
- What does Strata Critical Medical, Inc. do?
- In its own words, from Item 1 of its 10-K: "(f/k/a Blade Air Mobility, Inc.) (“Strata” or the “Company”) is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated “one call” solution for donor organ recovery."
- What is Strata Critical Medical, Inc.'s revenue?
- $197M for the fiscal year ending December 31, 2025, from its 10-K filed March 3, 2026.
- Is Strata Critical Medical, Inc. profitable?
- Strata Critical Medical, Inc. reported net income of $41.3M for the fiscal year ending December 31, 2025.
- How many employees does Strata Critical Medical, Inc. have?
- About 601 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Strata Critical Medical, Inc.?
- Will Heyburn, Co-CEO and CFO, as named in a 8-K filed November 3, 2026.
- Who is the CFO of Strata Critical Medical, Inc.?
- Will Heyburn, Co-CEO and CFO, as named in a 8-K filed November 3, 2026.
- Where is Strata Critical Medical, Inc. headquartered?
- New York, NY.
- What is Strata Critical Medical, Inc.'s stock ticker?
- SRTA on Nasdaq.
- What industry is Strata Critical Medical, Inc. in?
- Transportation Services, SIC code 4700.
- What is Strata Critical Medical, Inc.'s website?
- stratacritical.com.
- When does Strata Critical Medical, Inc. report earnings next?
- November 9, 2026. Source: pg_earnings_events.
- Is Strata Critical Medical, Inc. a public company?
- Yes. Strata Critical Medical, Inc. files with the SEC under CIK 0001779128 and trades as SRTA.
- Who audits Strata Critical Medical, Inc.?
- Deloitte & Touche LLP, New York, New York, as named in its latest annual report (10-K).
- How many shares of Strata Critical Medical, Inc. are outstanding?
- 89.3 million shares as of October 26, 2026, from its 10-Q filed November 3, 2026.
- What is Strata Critical Medical, Inc.'s public float?
- $264M as of June 30, 2025, as reported on the cover of its 10-K filed March 3, 2026.
- How many business segments does Strata Critical Medical, Inc. report?
- 2 reportable segments for the period ending September 30, 2026, from its 10-Q filed November 3, 2026.
- When is Strata Critical Medical, Inc.'s annual shareholder meeting?
- May 28, 2026, per its proxy statement (DEF 14A) filed April 14, 2026.
- Have Strata Critical Medical, Inc. insiders traded stock recently?
- Since August 4, 2025, officers and directors reported 11 open-market sales worth about $1.4M and 3 purchases worth about $108K on Forms 4 and 5. The most recent: Andrew Lauck (Director) bought 2,000 shares on November 5, 2026.